QT Vascular in potential sale of coronary products
Add BT as a preferred sourceMEDICAL technology firm QT Vascular is potentially selling its coronary products to a multinational firm.
In an announcement on Monday morning, it said that the term sheet both have entered into is non-legally binding and non-definitive, and it will continue to engage the buyer with the intention to complete the deal.
The Catalist-listed firm aims to continue generating value for shareholders from its mature products while further developing its drug-coated products and expanding its portfolio with new technologies, it added.
QT Vascular had also announced a potential transaction linked to certain coronary assets in October last year, which led to a surge in its share price.
Share with us your feedback on BT's products and services
TRENDING NOW
How BYD disrupted Singapore’s car market – and why the strategy is turning on itself
Too little, too late? Manila’s billion-dollar bid to ignite its sputtering EV industry
Vietnam seeks US$76 billion a year from capital markets to ease reliance on banks
MSCI drops S-E Asian heavyweights Sembcorp, GoTo and Ayala Land from global benchmarks
